Received Sep 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
Extra dose; Out of age; Out of age; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 58-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) for prophylaxis. Concurrent medical conditions included hiv infection. On 05-JUN-2025, the patient received the 2nd dose of Menveo. In APR-2024, the patient received the 1st dose of Menveo. In APR-2024 after receiving Menveo and an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: Out of age). On 05-JUN-2025, the patient experienced extra dose administered (Verbatim: Extra dose) and inappropriate age at vaccine administration (Verbatim: Out of age). The outcome of the extra dose administered, inappropriate age at vaccine administration and inappropriate age at vaccine administration were not applicable. Additional Information: GSK Receipt Date: 14-AUG-2025 The reporter called to get guidance on the vaccines series of Menveo for primary vaccination since the patient has a specific condition (HIV). She mentioned that according to the CDC, the time frame between the two doses was a minimum of 8 weeks for patients with HIV. The 58-year-old patient had the first dose back in April 2024 and he received the second dose on 5th June 2025, which led to inappropriate age at vaccine administration and extra dose administered. The reporter asked if a complete vaccination series or does he need a booster. The patient was planning to receive the booster dose at the time of reporting.
HIV infection